(Q44197234)

30 November 2017

title

Relations of clinical features, subgroups and medication to serum monoamines in schizophrenia (English)

1 reference

30 November 2017

1 reference

Robert D Oades

1

1 reference

30 November 2017

Ansgard Klimke

series ordinal

2

1 reference

30 November 2017

Uwe Henning

series ordinal

3

1 reference

30 November 2017

Marie Luise Rao

series ordinal

4

1 reference

30 November 2017

publication date

1 January 2002

1 reference

30 November 2017

published in

Human Psychopharmacology

1 reference

30 November 2017

volume

17

1 reference

30 November 2017

issue

1

1 reference

30 November 2017

page(s)

15-27

1 reference

Assessment of the Central Dopaminergic Index of Plasma HVA in Schizophrenia

30 November 2017

cites work

1 reference

Negative v positive schizophrenia. Definition and validation.

21 January 2018

1 reference

Conditioned blocking and schizophrenia: a replication and study of the role of symptoms, age, onset-age of psychosis and illness-duration.

21 January 2018

1 reference

The role of serotonin in schizophrenia

21 January 2018

1 reference

Neurotransmitter interactions in schizophrenia--therapeutic implications

21 January 2018

1 reference

Schizophrenia: syndromes and diseases.

21 January 2018

1 reference

Dopamine and 5-HT turnover are increased by the mGlu2/3 receptor agonist LY379268 in rat medial prefrontal cortex, nucleus accumbens and striatum.

21 January 2018

1 reference

Peripheral markers of serotonergic and noradrenergic function in post-pubertal, caucasian males with autistic disorder.

21 January 2018

1 reference

Plasma prolactin and plasma homovanillic acid: predictors of clinical response in schizophrenia.

21 January 2018

1 reference

The role of norepinephrine in the pathophysiology of cognitive disorders: potential applications to the treatment of cognitive dysfunction in schizophrenia and Alzheimer's disease

21 January 2018

1 reference

Explaining the symptoms of schizophrenia: Abnormalities in the awareness of action

21 January 2018

1 reference

Evolution of plasma homovanillic acid (HVA) in chronic schizophrenic patients treated with haloperidol.

21 January 2018

1 reference

Gating of information flow within the limbic system and the pathophysiology of schizophrenia

21 January 2018

1 reference

Clozapine response and plasma catecholamines and their metabolites

21 January 2018

1 reference

Relationship between plasma and cerebrospinal fluid norepinephrine and dopamine metabolites in a nonhuman primate

21 January 2018

1 reference

Origins and significance of dopa and catecholamine metabolites in body fluids

21 January 2018

1 reference

Psychotic symptoms resulting from intraventricular infusion of dopamine in Parkinson's disease

21 January 2018

1 reference

Relationship of psychotic symptoms to haloperidol-stimulated prolactin release.

21 January 2018

1 reference

Imaging D2 receptor occupancy by endogenous dopamine in humans

21 January 2018

1 reference

Neurochemistry and neuroendocrinology of schizophrenia: a selective review

21 January 2018

1 reference

Schizophrenia, psychosis, and cerebral spinal fluid homovanillic acid concentrations

21 January 2018

1 reference

Platelet serotonin, plasma cortisol, and dexamethasone suppression test in schizophrenic patients

21 January 2018

1 reference

Auditory P50 in schizophrenics on clozapine: improved gating parallels clinical improvement and changes in plasma 3-methoxy-4-hydroxyphenylglycol.

21 January 2018

1 reference

Neuropsychological and conditioned blocking performance in patients with schizophrenia: assessment of the contribution of neuroleptic dose, serum levels and dopamine D2-receptor occupancy.

21 January 2018

1 reference

A biomodal distribution of plasma HVA/MHPG in the psychoses.

21 January 2018

1 reference

Cerebrospinal fluid and plasma monoamine metabolites and their relation to psychosis. Implications for regional brain dysfunction in schizophrenia.

21 January 2018

1 reference

Modification of the radioreceptor assay technique for estimation of serum neuroleptic drug levels leads to improved precision and sensitivity

21 January 2018

1 reference

Serum amino acids, central monoamines, and hormones in drug-naive, drug-free, and neuroleptic-treated schizophrenic patients and healthy subjects

21 January 2018

1 reference

Somatosensory evoked potentials as indicators of altered cerebral excitability during psychotropic drug treatment.

21 January 2018

1 reference

Clozapine increases dopamine release in prefrontal cortex by 5-HT1A receptor activation

21 January 2018

1 reference

Blood biogenic amines during clozapine treatment of early-onset schizophrenia.

21 January 2018

1 reference

Pretreatment plasma homovanillic acid in schizophrenia and schizoaffective disorder: the influence of demographic variables and the inpatient drug-free period

21 January 2018

1 reference

Plasma homovanillic acid, plasma anti-D1 and -D2 dopamine-receptor activity, and negative symptoms in chronically mediated schizophrenia

21 January 2018

1 reference

Plasma homovanillic acid in untreated schizophrenia--relationship with symptomatology and sex.

21 January 2018

1 reference

Relationships between clinical effects and monoamine metabolites and amino acids in sulpiride-treated schizophrenic patients

21 January 2018

1 reference

Noradrenergic and dopaminergic interrelation in schizophrenia

21 January 2018

1 reference

The effect of clozapine on plasma norepinephrine: relationship to clinical efficacy

21 January 2018

1 reference

New Insights into the Biology of Schizophrenia through the Mechanism of Action of Clozapine

21 January 2018

1 reference

Dopamine uptake by platelets from subjects with schizophrenia: a correlation with the delusional state of the patient

21 January 2018

1 reference

Determination of catecholamines in rat heart tissue and plasma samples by liquid chromatography with electrochemical detection

21 January 2018

1 reference

Exaggerated responsivity of brain dopaminergic system activity in schizophrenia: a preliminary finding of increased variance of plasma homovanillic acid level in a chronic patient

21 January 2018

1 reference

Etiologic heterogeneity of the psychoses: is there a dopamine psychosis?

21 January 2018

1 reference

Determination of plasma homovanillic acid by liquid chromatography with electrochemical detection

21 January 2018

1 reference

Physiological characteristics of platelet/circulatory serotonin: study on a large human population

21 January 2018

1 reference

21 January 2018

1 reference

Relationships between interleukins, neurotransmitters and psychopathology in drug-free male schizophrenics

21 January 2018

1 reference

m-Chlorophenylpiperazine effects in neuroleptic-free schizophrenic patients. Evidence implicating serotonergic systems in the positive symptoms of schizophrenia

21 January 2018

1 reference

Syndromes of chronic schizophrenia

21 January 2018

1 reference

Estimates of Dopamine and Serotonin Synthesis by the Awake Human Brain

21 January 2018

1 reference

Biogenic amine metabolites in plasma of drug-naive schizophrenic patients: Associations with symptomatology

21 January 2018

1 reference

Major psychosis and dopamine: controversial features and some suggestions

21 January 2018

1 reference

Determination of free 3-methoxy-4-hydroxyphenylglycol with several other monoamine metabolites in plasma by high-performance liquid chromatography with amperometric detection

21 January 2018

1 reference

Schizophrenic patients with deficit syndrome have higher plasma homovanillic acid concentrations and ventricular enlargement

21 January 2018

1 reference

Plasma homovanillic acid as an index of brain dopamine metabolism: enhancement with debrisoquin

21 January 2018

1 reference

Prediction of short-term changes in symptom severity by baseline plasma homovanillic acid levels in schizophrenic patients receiving clozapine

21 January 2018

1 reference

Plasma 3-methoxy-4-hydroxyphenylglycol and homovanillic acid measurements in deficit and nondeficit forms of schizophrenia

21 January 2018

1 reference

The psychobiology of first-episode schizophrenia.

21 January 2018

1 reference

Effect of risperidone on plasma free 3-methoxy-4-hydroxyphenylglycol (pMHPG) levels in schizophrenic patients: relationship among plasma concentrations of risperidone and 9-hydroxyrisperidone, pMHPG levels, and clinical improvement

21 January 2018

1 reference

Neurotransmitter systems in schizophrenia.

21 January 2018

1 reference

inferred from DOI database lookup

7 January 2021

based on heuristic

Guidelines for the dosage of neuroleptics. II: Changing from daily oral to long acting injectable neuroleptics

1 reference

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1002/HUP.368

1 reference

30 November 2017

1 reference